David Kandzari
Latest contributions
Clinical adoption of renal denervation: no more excuses
15 May 2024 – From EuroPCR 2024
Effect of alcohol-mediated renal denervation on blood pressure in the presence of antihypertensive drugs: 3-month primary results from the TARGET BP I Randomized Trial
08 Apr 2024
Alessandro Sticchi interviews David E. Kandzari about the results of the Target Bp I Randomized Trial which he presented at ACC.24.
The trial reports mixed results on nerve ablation for high blood pressure with a modest but statistically significant difference in lowered blood pressure at 3 months,...
Author
Author
Challenging CTO procedures
18 May 2023 – From EuroPCR 2023
Witness these cases centered around chronic total occlusion procedures and develop expertise in the treatment of situations that often remain a challenge. Topics covered include -Retrograde and antererograde approach in patient with double CTO under IVUS guidance intervention- CTO PCI in multivessel coronary artery- Explore these...
Bifurcations
17 May 2023 – From EuroPCR 2023
Seeking to revive your understanding of this session focusing on bifurcations? Examine these slides and review the main elements of the presentations.
Hypertension management in 2022: Latest data on renal denervation
17 May 2022 – From EuroPCR 2022
Ali Nazmi Calik discusses with David Kandzari the current data on the catheter-based renal denervation treatment to reduce blood pressure in patients with hypertension. They discuss more specifically the results from SPYRAL HTN-ON MED 3-year data, the 3-year Global SYMPLICITY Registry and RADIANCE-HTN SOLO and TRIO...
Stents in challenging situations
18 May 2022 – From EuroPCR 2022
Watch this session to discover the use and outcome of a selection of abstract submissions concerning: the treatment of diffuse CAD with one long stent vs. multistents, novel uncaging bioadaptor for coronary revascularisation, one-month DAPT in high bleeding risk ACS patients and much more.
Advances in renal denervation: from patient selection to procedure
17 May 2022 – From EuroPCR 2022
For this EuroPCR 2022 session, Felix Mahfoud is joined by David Kandzari, Rasha Al-Lamee, Flavio Ribichini, and Andrew Sharp to talk about renal denervation: hear real-life experiences and get the latest preclinical and clinical data on the long-term safety and efficacy of the radiofrequency renal denervation...
EuroPCR 2022 Hotlines / Late-Breaking Trials in hypertension management: SPYRAL-HTN ON MED, radiance HTN SOLO and TRIO, and more!
17 May 2022 – From EuroPCR 2022
Find out more about various studies & registries in hypertension management! Blood pressure and MACE reductions after renal denervation: 3-year GSR results, patient-level pooled analysis of ultrasound RDN in radiance-HTN SOLO and Trio, and SPYRAL-HTN ON MED 3 year data.
Redefining hypertension management with renal denervation
19 May 2021 – From EuroPCR 2021
Watch this session presented by Jeffrey Popma, David Kandzari, Felix Mahfoud and Andrew Sharp in order to understand the latest data on the safety and efficacy of radiofrequency renal denervation including future studies, to learn about the long-term durability of renal denervation in a real-world patient population, and...
A case-based approach: finding balance between bleeding and ischemic risk
19 May 2021 – From EuroPCR 2021
Watch this session presented by David Kandzari, Mirvat Alasnag, Emmanouil Brilakis, Chorcheung Frankie Tam and Beatriz Vaquerizo in order to debate case complexity of patient characteristics and complex lesions in HBR patients, to review patient centered clinical judgment and individualised treatment plans, and to analyse current Onyx ONE...
